Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma

@article{Mohammad1998SynergisticIO,
  title={Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma},
  author={R. Mohammad and G. Pettit and V. P. Almatchy and N. Wall and M. Varterasian and Ayad M. Ai-Katib},
  journal={Anti-Cancer Drugs},
  year={1998},
  volume={9},
  pages={149–156}
}
  • R. Mohammad, G. Pettit, +3 authors Ayad M. Ai-Katib
  • Published 1998
  • Biology, Medicine
  • Anti-Cancer Drugs
  • We studied the antitumor effects of dolastatin 10, its structural modification, auristatin PE (TZT-1027), and vincristine alone and in combination with bryostatin 1 on a human diffuse large cell lymphoma line (WSU-DLCL2) in vitro and in vivo. WSU-DLCL2 cells were cultured in RPMI 1640 at a concentration of 2 × 105/ml using a 24-well plate. Agents were added to triplicate wells, and cell count, viability, mitosis and apoptosis were assessed. Dolastatin 10 showed no apparent inhibition of cell… CONTINUE READING
    20 Citations
    TZT‐1027, an Antimicrotubule Agent, Attacks Tumor Vasculature and Induces Tumor Cell Death
    • 73
    Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma.
    • 119
    Pharmacology and clinical experience with bryostatin 1: a novel anticancer drug.
    • Philip, Zonder
    • Medicine
    • Expert opinion on investigational drugs
    • 1999
    • 27